. Author manuscript; available in PMC: 2023 Oct 10.

Published in final edited form as: J Rheumatol. 2019 Apr 1;47(3):431–440. doi: 10.3899/jrheum.180233

Table 2.

Baseline characteristics in those who had unguided and ultrasound-guided injections.

Variables	Participants with Unguided Injection	Participants with Ultrasound-guided Injection
N	120	79
Age, yrs, mean (SD)	62.3 (10.3)	63.5 (10.4)
Females, frequency (%)	62 (51.7)	43 (54.4)
No. days to followup appointment	8.0 (7.0–14.0)	8.0 (7.0–14.0)
KOOS pain subscale score (0–100)^*	44.4 (36.1–55.6)	41. 7 (36.1–52.8)
Pain on nominated activity VAS (0–10)^**	7.0 (5.5–7.7) ^¤	7.2 (5.8–8.4) ^†
Pain in last week VAS (0–10)^**	6.5 (4.7–7.8) ^¤	6.6 (5.3–8.3) ^†
No. responders to injection, at followup visit, frequency (%)	85 (70.8)	61 (77.2)

Values are median (IQR) unless otherwise specified.

KOOS pain subscale is scored from 100 (no pain) to 0 (extreme pain).

^**

VAS is scored from 0 (no pain) to 10 (pain as bad as you can imagine).

^¤

N = 5 and 3 participants neglected to complete their pain on nominated activity VAS and pain in last week VAS, respectively.

^†

N = 4 and 2 participants neglected to complete their pain on nominated activity VAS and pain in last week VAS, respectively. IQR: interquartile range; KOOS: Knee Injury and Osteoarthritis Outcome Score; VAS: visual analog scale.